Improving memory in older adults with mild cognitive impairment
Improvement of Memory in Mild Cognitive Impairment (MCI) Using Transcranial Alternating Current Stimulation (tACS) Guided by EEG and MRI: a Randomized, Sham-controlled, Parallel-arm, Double-blind Study
This study is testing if a new brain stimulation technique led by caregivers can help older adults with mild memory problems improve their memory.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 55 Years to 85 Years |
| Sex | All |
| Sponsor | University of Geneva, Switzerland Academic / other |
| Locations | 1 site (Geneva) |
| Trial ID | NCT05708001 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the feasibility and effectiveness of remote, caregiver-led transcranial alternating current stimulation (tACS) for older adults experiencing memory decline. The study aims to determine if repeated tACS can lead to sustained improvements in neuronal activity and memory functions. Participants will undergo a comprehensive clinical assessment to confirm mild cognitive impairment and will be monitored for safety and efficacy throughout the intervention. The findings will inform future research on home-based tACS as a treatment option for memory decline.
Who should consider this trial
Good fit: Ideal candidates include older adults aged 55 and above diagnosed with mild cognitive impairment.
Not a fit: Patients with severe cognitive impairment or those unable to comply with study requirements may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance memory function and quality of life for older adults with mild cognitive impairment.
How similar studies have performed: Other studies have shown promise with tACS in cognitive enhancement, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Mild Cognitive Impairment (MCI) patients * age ≥ 55 years old * clinical diagnosis of mild cognitive impairment (MCI) based on a comprehensive clinical assessment and standard neuropsychological examination including tests of language, visuospatial thinking, executive functions, and memory * confirmation of diagnosis will be made by Prof. Paul Unschuld, the study MD, based on a participant's cognitive evaluation and history * understanding of the informed consent * able and willing to comply with all study requirements * informed consent form was signed * women of childbearing potential (WOCBP) must perform a pregnancy test during screening Caregiver * minimum 21 years of age * self-reported computer/tablet proficiency * willingness to learn how to use tACS * availability during the study period to administer tACS to the participant * informed consent form was signed * women of childbearing potential (WOCBP) must perform a pregnancy test during screening Exclusion Criteria: Mild Cognitive Impairment (MCI) patients * age \< 55 years old * any current diagnosis of a psychiatric disorder (e.g., schizophrenia, bipolar disorder, depressive disorder) * other than MCI, any history of other progressive or genetic neurologic disorder (e.g., Parkinson's disease, multiple sclerosis, tubular sclerosis) or acquired neurological disease (e.g., stroke, traumatic brain injury, tumor), including intracranial lesions * history of head trauma resulting in prolonged loss of consciousness * current history of poorly controlled headaches including chronic medication for migraine prevention * history of fainting spells of unknown or undetermined etiology that might constitute seizures * history of seizures, diagnosis of epilepsy * any unstable medical condition or chronic uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) * contraindication for undergoing MRI or receiving tACS * any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g., MRI compatible joint replacement) * any skin problems, such as dermatitis, psoriasis, or eczema * any electrically, magnetically, or mechanically activated implanted devices such as a pacemaker, intracranial electrodes, implanted defibrillators, medication pumps, nerve stimulators, vascular clips, or any other prosthesis in the brain * any serious life-threatening disease such as congestive heart failure, pulmonary obstructive chronic disease, or active neoplasia * pregnant women * adults lacking capacity for consent Caregiver * insufficient understanding of study procedures * poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tACS
Where this trial is running
Geneva
- University of Geneva, Campus Biotech — Geneva, Switzerland (Recruiting)
Study contacts
- Principal investigator: Lucie Bréchet, PhD — University of Geneva (UNIGE)
- Study coordinator: Lucie Bréchet, PhD
- Email: lucie.brechet@unige.ch
- Phone: +41 22 379 08 52
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.